________________
News ImaCor Introduces the
Zura EVO™
New touch screen hTEE imaging platform released globally
Garden City, NY - July 9, 2012 - ImaCor Inc., the pioneer of the world's only hemodynamic transesophageal echocardiography (hTEE™) management device, today released the Zura EVO™ ultrasound system. This next-generation imaging platform is used with ImaCor's miniaturized, disposable ClariTEEŽ probe. |
|
__________________
The European Society of Intensive Care Medicine (ESICM) will host its annual meeting in Lisbon, Portugal, beginning on Sunday October 14, 2012 through Wednesday October 17, 2012.
ImaCor is pleased to participate in the pre-congress Advanced Hemodynamic Monitoring Course at ESICM this Fall.
|
Course
Mailing List Would you like to be alerted to upcoming hTEE courses?
Join our mailing list:
courses@imacorinc.com
or contact
Geeta Surti
1-516-393-0970 x113 |
Testimonial
"The ClariTEE probe is a very valuable tool because it changes patient management 60-80% of the time according to our patient population. As a surgeon, it reassures me that I am making the right decision in treating these complex patients."
Simon Maltais MD, PhD
Vanderbilt University Medical Center |
 | |
Nicholas Cavarocchi MD from Thomas Jefferson University Hospital instructing first year surgical intern and nurse practitioner on the Zura system.
|
|
 | |
Dennis Ashley MD, Chief of Trauma Services, from the Medical Center of Central Georgia utilizing a ClariTEE probe.
|
|
 | |
Inservice training led by ImaCor's Scott Morgan RDCS, RVT.
|
|
 | |
Mladen Sokolovic MD from Washington Hospital Center guiding ClariTEE probe while Tia Boylan RDCS, left, observes.
|
|
 | |
Scott Roth MD, Chief Medical Officer of ImaCor Inc. at the EBPOM conference in London, Great Britain. Dr. Roth, standing, is providing hTEE instruction.
|
|
|
Contact Us
1-516-393-0970 or
1-877-244-0657
|
|
*****
Should you wish to submit an article to our next monthly newsletter,
please contact:
Sheila McGarrigle at
|
|
|
|
|
 
The Role of hTEE in the VAD Process - An Interview with Simon Maltais MD, PhD
Vanderbilt University Medical Center
(Excerpts, click here to read the interview)
 | | Simon Maltais MD, PhD |
Q. Have you always used TEE in your practice? Why?
Where I trained at Mayo we routinely had a need for a "quick look" at the echo. We didn't need the whole system [conventional TEE], just a quick look. You need to reassure yourself and the echo provides that.
We just wrote this paper here at Vanderbilt where we show that the ClariTEE probe changed management, in our patient population about 60-80% of the time approximately from what we would have normally done clinically.
Q. You put a probe in once they get to the ICU?
Yes. We are working on a protocol where we obtain images every eight hours, systematically to make sure we are heading in the right direction.
Q. Is there an economic benefit from using the probe?
One avoided RV or one saved re-op (reoperation) can pay for it. The RVAD itself is $35,000. Or what is the cost of spending one less day in the ICU? In a patient with moderate RV dysfunction, I really want to have the ImaCor system for the continuous examination of the heart...
Read More
Share:    
|
|
hTEE-guided Rapid Weaning From Pressors in a Post-Cardiac Surgery Patient with an Ischemic Gut
Jiri Horak MD
Hospital of the University of Pennsylvania
(Excerpted, To Read the Case Report, Click Here)
 | | Jiri Horak MD |
This case report describes the use of a miniaturized
transesophageal echo probe (ClariTEEŽ, ImaCor Inc. Garden City, NY) to diagnose and monitor hemodynamic instability in a patient following surgery for an occluded superior mesenteric artery due to aortic dissection. Hemodynamic TEE (hTEE™) management revealed the specific cause of hemodynamic instability as severe diastolic dysfunction. Continued hTEE management allowed the physician to confidently and rapidly wean down pressors. This was particularly important as excessive pressors in this patient could have caused further gut ischemia, inflammatory mediator release, and further diastolic dysfunction.
Case Report:
A 37-year-old man with a history of hypertension initially presented with a ruptured type A dissection. He underwent aortic valve resuspension, total arch replacement, and replacement of the ascending aorta. Echo on post-op day five showed normal biventricular function. . .
Read More
Share:
Back to Top
|
|
Assessment of Hypotension in the PACU Following Spinal Fusion Using Transesophageal Echocardiographic Management
Performed by Jesse Marymont MD
NorthShore University Hospital
(previously Evanston Hospital, Evanston, IL)
(Excerpted, To Read the Case Report, Click Here)
Objective
 | |
Click to play cineloop
|
Diagnose source of post-surgical hypotension in the post-anesthesia care unit (PACU).
Background
A 77-year-old female weighing 48 kg presented with multiple myeloma which had collapsed her T12 vertebrae.
 | |
Click to play cineloop
|
During the operation her blood loss was 1700 ml and urine was 400 ml. IV fluids were 4500 ml with 4 units of PRBC and 250 ml Hespan. Patient was hypotensive (70-80) in the PACU after being administered .75 liters of fluid and neosynepherine.
Read More
Share:
Back to Top
|
80 Seconds to Decision by Chad E. Wagner MD
Vanderbilt University Medical Center
Back to Top
|
hTEE = On Demand When You Need It, In For the Long Haulby Harold Hastings PhD It is now four years since our first post-clearance evaluation session with Dr. Jesse Marymont of North Shore University Hospital in Evanston, IL. At that time, we were getting set up for a routine hTEE case with another physician there, when Dr. Marymont asked us to rush down to the PACU to help him identify the cause of hemodynamic instability: a 48 kg female patient had become hemodynamically unstable post spinal surgery (systolic BP 70-80 mmHg and falling despite a positive fluid balance of 3.4 L and significant pressor support). After placing an hTEE probe, Dr. Marymont diagnosed the cause of the patient's instability as hypovolemic shock, and administered additional fluids stat. Dr. Marymount continued to use hTEE to help manage fluids and vasoactive support...
Back to Top
|
New Technology Assessment - Controlling Uncertaintyby Rich Lanzillotto
Director of Regulatory Affairs & Quality Assurance, ImaCor Inc.
(Excerpted, click here to read full report) When new technologies are proposed to improve patient outcomes and reduce costs, hospitals seek to control the uncertainty of the new technology. Risk arises from this uncertainty which includes the effect the new technology will have on patient outcomes and the effect it will have on the hospital's budget. This article describes ImaCor's new technology assessment (NTA) procedure for its critical care hTEE technology and recommends it as a model that addresses the various uncertainties. The ImaCor NTA approach includes partnering with the hospital, and sharing the risk of the assessment. This includes cost variables like training and device placement. An ImaCor clinical specialist will be on hand to facilitate training of the technology. For the hospital, a point person is needed to facilitate the assessment logistics on the hospital side. |
ImaCor to Host hTEE Evening Symposium in Lisbon, Portugal
 ImaCor is pleased to host a special academic evening immediately the first evening session of the ESICM on Sunday, October 14, 2012. The event will be held at the beautiful Lapa Palace in Lisbon, Portugal.
We have a distinguished group of physicians who will speak on their studies and experiences with hTEE. Speakers include Jan Bakker, MD, PhD, Maurizio Cecconi MD, PhD, Daniel De Backer MD, PhD, Nick Fletcher MD, Paul Mayo MD, Michael R. Pinsky, MD, Dr hc, MCCM, FCCP, Jan Poelaert MD, PhD, Michel Slama MD, PhD, Antoine Vieillard-Baron MD, PhD, and Philippe Vignon MD, PhD.
There are limited invitations available to attend this educational event. If you are interested in learning more please register your interest in attending at http://imacorinc.com/lisbon-reception.html.
Back to Top |
 As we advance into the second half of the year, we continue to drive patient benefits in trauma and heart failure. Establishing clinical protocols to define unit-by-unit hTEE use plays a prominent role in optimizing patient care. In May, Mike Chang MD from Wake Forest University Baptist Medical Center presented their trauma/acute care surgery service algorithm for hTEE support; this month Simon Maltais MD, PhD from Vanderbilt University Medical Center described the development of his team's protocol to obtain hTEE images every eight hours in their post-placement VAD patients. With the number of hTEE cases now over 2,000, our users are systemizing probe placement for maximum patient benefit and LOS reduction in their ICUs.
We recognize that as each clinical user site customizes its individual hTEE use algorithm, our objective must remain on providing advanced solutions that constantly improve its global application. Beyond ongoing research and development of our technology, we also continue to improve and simplify the hTEE approach and all educational initiatives. The Reading Room online module, our gratis 1-day hTEE courses, and repeated participation in society-led advanced hemodynamic monitoring courses are all impactful in that regard.
Our primary objective to improve patient care has led us to a new endeavor: the hTEE technology assessment. Repeatedly our physicians share with us stories of how use of hTEE has significantly changed and improved patient management; they also tell us of their challenges in best reporting this to their administrators. To that end, we have developed and tested the hTEE new technology assessment as a means for us to partner with administration at hTEE sites and further support- together- the work of our physicians. Rich Lanzillotto's article this month provides a comprehensive overview to this cost justification model (ROI), a clean, concise approach to cost/benefit discussions.
Finally, this second half of 2012 brings with it the completion of a series of European and US studies currently underway. I am very encouraged by all of the preliminary findings and await the opportunity to formally share the published results with you. In the interim, perhaps you will join us this October for our hTEE Evening Symposium at the exquisite Lapa Palace, a prestigious 19th century estate in Lisbon, Portugal. We are honored to have 10 of the most prominent international medical professors and visionaries speaking about their hTEE experiences and studies. I do hope you will attend.
With warmest regards,
Peter Pellerito
President & CEO
Share:
|
|
|
|
|
